J. Alvar, I. D. Vélez, C. Bern, M. Herrero, P. Desjeux et al., Leishmaniasis worldwide and global estimates of its incidence, PLoS One, vol.7, 2012.

C. Asela, C. Cruz, F. Alves, S. Robledo, and B. Arana, A phase II study to evaluate the safety and efficacy of topical 3 % amphotericin B cream ( Anfoleish ) for the treatment of uncomplicated cutaneous leishmaniasis in, PLoS Neglected Trop. Dis, vol.13, pp.1-12, 2018.

I. S. Barsoum, K. M. Kopydlowski, P. Cuenin, and J. A. Setterstrom, Evaluation of hypersensitivity to microencapsulated ampicillin in Guinea pigs, J. Antimicrob. Chemother, vol.39, pp.63-69, 1997.

A. Ben-salah, N. Ben-messaoud, E. Guedri, A. Zaatour, N. Ben-alaya et al., Topical paromomycin with or without gentamicin for cutaneous leishmaniasis, N. Engl. J. Med, vol.368, pp.524-532, 2013.
URL : https://hal.archives-ouvertes.fr/pasteur-00793585

K. Bocxlaer, Y. Van, V. Murdan, S. Croft, and S. L. , Drug permeation and barrier damage in Leishmania-infected mouse skin, J. Antimicrob. Chemother, vol.71, pp.1578-1585, 2016.

K. Corware, D. Harris, I. Teo, M. Rogers, K. Naresh et al., Accelerated healing of cutaneous leishmaniasis in non-healing BALB/c mice using water soluble amphotericin B-polymethacrylic acid, Biomaterials, vol.32, pp.8029-8039, 2011.

S. H. Dayan, J. Schlessinger, K. Beer, L. M. Donofrio, D. H. Jones et al., Treatment session: pooled analysis of Data from the phase 3 REFINE trials, Aesthet. Surg. J, vol.38, pp.998-1010, 2018.

. Dndi, DNDi's Strategy for Cutaneous Leishmaniasis, 2017.

I. Esfandiarpour, S. Farajzadeh, Z. Rahnama, E. A. Fathabadi, and A. Heshmatkhah, Adverse effects of intralesional meglumine antimoniate and its influence on clinical laboratory parameters in the treatment of cutaneous leishmaniasis, Int. J. Dermatol, vol.51, pp.1221-1225, 2012.

E. Fröhlich, The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles, Int. J. Nanomed, vol.7, pp.5577-5591, 2012.

S. C. Gad, The mouse ear swelling test (MEST) in the 1990s, Toxicology, vol.93, pp.33-46, 1994.

M. Gaumet, A. Vargas, R. Gurny, and F. Delie, Nanoparticles for drug delivery: the need for precision in reporting particle size parameters, Eur. J. Pharm. Biopharm, vol.69, pp.1-9, 2008.

V. M. Goyonlo, E. Vosoughi, B. Kiafar, Y. Nahidi, A. Momenzadeh et al., Efficacy of intralesional amphotericin B for the treatment of cutaneous leishmaniasis, Indian J. Dermatol, vol.59, pp.631-636, 2014.

E. Grela, M. Piet, R. Luchowski, W. Grudzinski, and R. Paduch, Imaging of human cells exposed to an antifungal antibiotic amphotericin B reveals the mechanisms associated with the drug toxicity and cell defence, Sci. Rep. 1, 2018.

J. L. Italia, M. M. Yahya, D. Singh, and M. N. Kumar, Biodegradable nanoparticles improve oral bioavailability of amphotericin B and show reduced nephrotoxicity compared to intravenous Fungizone ®, Pharm. Res. (N. Y.), vol.26, pp.1324-1331, 2009.

I. Kevric, M. A. Cappel, and J. H. Keeling, New world and old world Leishmania infections: a practical review, Dermatol. Clin, vol.33, pp.579-593, 2015.

P. Legrand, . Vertut-doï, and J. Bolard, Comparative internalization and recycling of different amphotericin B formulations by a macrophage-like cell line, J. Antimicrob. Chemother, vol.37, pp.519-533, 1996.

H. C. Lima, J. A. Bleyenberg, and R. G. Titus, A simple method for quantifying Leishmania in tissues of infected animals, Parasitol. Today Off, vol.13, pp.40010-40012, 1997.

L. López, M. Robayo, M. Vargas, and I. D. Vélez, Thermotherapy. An alternative for the treatment of American cutaneous leishmaniasis, Trials, vol.13, pp.1-7, 2012.

H. K. Makadia and S. Steve, Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier, Polymers, vol.3, pp.1377-1397, 2011.

E. R. Mears, F. Modabber, R. Don, and G. E. Johnson, A Review: the current in vivo models for the discovery and utility of new anti-leishmanial drugs targeting cutaneous leishmaniasis, PLoS Neglected Trop. Dis, vol.9, pp.1-23, 2015.

V. C. Mendonça, V. T. Martins, D. P. Lage, D. S. Dias, P. A. Ribeiro et al., Comparing the therapeutic efficacy of different amphotericin B-carrying delivery systems against visceral leishmaniasis, Exp. Parasitol, vol.186, pp.24-35, 2018.

S. Mushtaq, D. Dogra, and N. Dogra, Clinical Response with intralesional Amphotericin B in the treatment of old world cutaneous leishmaniasis : a preliminary report, Dermatol. Ther, vol.29, pp.398-405, 2016.

A. B. Nair and S. Jacob, A simple practice guide for dose conversion between animals and human, J. Basic Clin. Pharm, vol.7, pp.27-31, 2016.

T. R. Navin, B. A. Arana, F. E. Arana, A. M. De-mérida, A. L. Castillo et al., Placebo-controlled clinical trial of meglumine antimonate (glucantime) vs . localized controlled heat in the treatment of cutaneous leishmaniasis in Guatemala, Am. J. Trop. Med. Hyg, vol.42, pp.43-50, 1990.

R. Nicolete, D. F. Santos, . Dos, and L. H. Faccioli, The uptake of PLGA micro or nanoparticles by macrophages provokes distinct in vitro inflammatory response, Int. Immunopharmacol, vol.11, pp.1557-1563, 2011.

T. Otsuka, H. Takagi, N. Horiguchi, M. Toyoda, K. Sato et al., CCl4-induced acute liver injury in mice is inhibited by hepatocyte growth factor overexpression but stimulated by NK2 overexpression, FEBS Lett, vol.532, pp.3714-3720, 2002.

R. E. Silva, A. T. Júnior, M. C. Senna, A. Rabello, and G. Cota, Intralesional meglumine antimoniate for the treatment of localised cutaneous leishmaniasis : a retrospective review of a Brazilian referral centre, Mem. Inst. Oswaldo Cruz, vol.111, pp.512-516, 2016.

N. Sosa, Z. Capitán, J. Nieto, M. Nieto, J. Calzada et al., Randomized, double-blinded, phase 2 trial of WR 279,396 (paromomycin and gentamicin) for cutaneous leishmaniasis in Panama, Am. J. Trop. Med. Hyg, vol.89, pp.557-563, 2013.

A. J. Sousa-batista, N. Arruda-costa, B. Rossi-bergmann, and M. I. Ré, Improved drug loading via spray drying of a chalcone implant for local treatment of cutaneous leishmaniasis, Drug Dev. Ind. Pharm, vol.18, pp.1-8, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01984692

A. J. Sousa-batista, W. Pacienza-lima, N. Arruda-costa, C. A. Falcão, M. I. Ré et al., Depot subcutaneous injection with chalcone CH8-loaded poly (Lactic-Co-Glycolic Acid) microspheres as a single-dose treatment of cutaneous leishmaniasis, Antimicrob. Agents Chemother, vol.62, pp.1822-1839, 2018.

S. R. Uliana, C. T. Trinconi, and A. C. Coelho, Chemotherapy of leishmaniasis: present challenges, Parasitology, vol.20, pp.1-17, 2017.

A. A. Voak, J. F. Standing, N. Sepu, A. Harris, S. L. Croft et al., Pharmacodynamics and cellular accumulation of amphotericin B and miltefosine in Leishmania donovani -infected primary macrophages, J. Antimicrob. Chemother, vol.73, pp.1314-1323, 2018.

Y. Wang, W. Qu, and S. H. Choi, FDA's Regulatory Science Program for Generic PLA/ PLGA -Based Drug Products, 2016.

, /Featured-Articles/188841-FDA-s-Regulatory-Science-Program-for-Generic-PLA-PLGA-Based-Drug-Products, Am. Pharm. Rev, 2016.

G. Wijnant, K. Bocxlaer, A. F. Van-francisco, V. Yardley, A. Harris et al., Local skin inflammation in cutaneous leishmaniasis as a source of variable pharmacokinetics and therapeutic efficacy of liposomal amphotericin B, Antimicrob. Agents Chemother, vol.62, pp.631-649, 2018.

G. Wijnant, K. Bocxlaer, Y. Van, V. Harris, A. Alavijeh et al., Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome ® and AmBisome ® in murine cutaneous leishmaniasis, IJP Drugs Drug Resist, vol.8, pp.223-228, 2018.

G. Wijnant, K. Bocxlaer, Y. Van, V. Harris, A. Murdan et al., AmBisome® treatment of murine cutaneous leishmaniasis: relation between skin pharmacokinetics and efficacy, Antimicrob. Agents Chemother, vol.62, pp.2009-02017, 2018.

X. Xie, W. Lin, C. Xing, Y. Yang, Q. Chi et al., In vitro and in vivo evaluations of PLGA microspheres containing nalmefene, PLoS One, vol.10, pp.1-19, 2015.

V. Yardley and S. L. Croft, Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis, Antimicrob. Agents Chemother, vol.41, pp.752-756, 1997.